Bonefos and the Consumption of Analgesics

Bonefos and the Consumption of Analgesics. Influence of Clodronate on Analgesics Consumption Among Patients With Bone Metastasis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00909142

Acronym

BICAM

Enrollment

149

Registered

2009-05-27

Start date

2007-04-30

Completion date

2009-02-28

Last updated

2012-04-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bone Neoplasms

Keywords

Breast cancer, Prostate cancer, Multiple myeloma

Brief summary

The effect of Bonefos on consumption of analgesics (drugs used for pain treatment) in patients with proven bone metastases.

Interventions

DRUGBonefos (Clodronate, BAY94-8393)

Patients in regular clinical practice receiving Bonefos according to local drug information

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Breast cancer or prostate cancer or multiple myeloma. * Bone metastasis. * Ability to use analgesics and clodronate 1600 mg/day.

Exclusion criteria

* Hypersensitivity to bisphosphonates. * Clodronate in previous therapy. * Concomitant use of other bisphosphonates. * Serious renal insufficiency.

Design outcomes

Primary

Measure	Time frame
Analgesics consumption after 12 months of treatment with Bonefos in patients with bone metastases and breast or prostate cancer or multiple myeloma	12 months

Secondary

Measure	Time frame
Decrease in pain measured by VAS (Visual Analogue Scale)	12 months

Countries

Czechia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026